(Updated - May 8, 2023 5:08 PM EDT)

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q1 EPS of ($0.15), $0.13 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $20.25 million versus the consensus estimate of $15.72 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

Earnings